L-Type amino acid transporter 1 as a target for drug delivery
L-тип аминокислотный транспортер 1 как мишень для доставки лекарственных средств
2020-05-01
SCID: 54.1/5zyerw4d
Discuss with AI
L-type amino acid transporter 1LAT1-mediated deliveryblood-brain barrierdrug prodrugstargeted drug delivery
Figures from the paper
Abstract (AI)
Abstract Our growing understanding of membrane transporters and their substrate specificity has opened a new avenue in the field of targeted drug delivery. The L-type amino acid transporter 1 (LAT1) has been one of the most extensively investigated transporters for delivering drugs across biological barriers. The transporter is predominantly expressed in cerebral cortex, blood-brain barrier, blood-retina barrier, testis, placenta, bone marrow and several types of cancer. Its physiological function is to mediate Na + and pH independent exchange of essential amino acids: leucine, phenylalanine, etc. Several drugs and prodrugs designed as LAT1 substrates have been developed to improve targeted delivery into the brain and cancer cells. Thus, the anti-parkinsonian drug, L-Dopa, the anti-cancer drug, melphalan and the anti-epileptic drug gabapentin, all used in clinical practice, utilize LAT1 to reach their target site. These examples provide supporting evidence for the utility of the LAT1-mediated targeted delivery of the (pro)drug. This review comprehensively summarizes recent advances in LAT1-mediated targeted drug delivery. In addition, the use of LAT1 is critically evaluated and limitations of the approach are discussed.
Key Findings
1
Clinically used L-Dopa, melphalan, and gabapentin utilize LAT1 for delivery to their target sites, supporting the utility of LAT1-mediated drug targeting.
2
LAT1 is a broadly investigated transporter for targeted drug delivery across biological barriers, including the blood-brain and blood-retina barriers.
3
LAT1 is predominantly expressed in the cerebral cortex, blood-brain barrier, blood-retina barrier, testis, placenta, bone marrow, and several cancers.
4
LAT1 mediates sodium- and pH-independent exchange of essential amino acids such as leucine and phenylalanine.
5
LAT1-substrate drug and prodrug design has been used to improve delivery into the brain and cancer cells.
6
The approach has demonstrated promise but requires critical evaluation because LAT1-mediated delivery has acknowledged limitations.
Research Object
L-type amino acid transporter 1 (LAT1)-mediated drug delivery across biological barriers and into brain and cancer cells
Research Subject
The utility, mechanisms, recent advances, and limitations of using LAT1 substrate drugs and prodrugs for targeted delivery
Publication Details
Publication Date
2020-05-01
Journal
Publisher
ISSN
Cited by
218
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest
References available in scid.ai2
Cited by7
Metabolism of Amino Acids in Cancer2021
Polymer-Based Drug Delivery Systems for Cancer Therapeutics2024
The Crucial Role of the Blood–Brain Barrier in Neurodegenerative Diseases: Mechanisms of Disruption and Therapeutic Implications2025
Review of the Correlation of LAT1 With Diseases: Mechanism and Treatment2020
Amino Acid-Based Boron Carriers in Boron Neutron Capture Therapy (BNCT)2023
Functional Characterization of the Solute Carrier LAT-1 (SLC7A5/SLC3A2) in Human Brain Capillary Endothelial Cells with Rapid UPLC-MS/MS Quantification of Intracellular Isotopically Labelled L-Leucine2022
L‑type amino acid transporter 1 in enhancing boron neutron capture therapy: Mechanisms, challenges and future directions (Review)2025